Ischemic Stroke Clinical Trial
Official title:
Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patients With Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial
Patients with acute ischemic stroke will be divided into 2 groups by double-blind,
randomized, and controlled trial. Personality and past history of the patients will be
recorded after the patients signed inform consent. The patient will be collected blood among
10 cc. for measurement biomarker in serum that related plaque stability for baseline and
obtained neurological examination for baseline.
The patients must be take pills for 180 days by randomized code number on pill box, and
patients must be turn into the site for follow up visit at Day 90 and Day 180. All visits of
the patients will be collected blood among 10 cc. for measurement biomarker in serum that
related plaque stability and obtained neurological examination.
Next, the data will be separated with code number for divided group into 2 groups. Group 1 is
simvastatin 10 mg per day treatment (n=36) and Group 2 is simvastatin 40 mg per day
treatment. Finally, all data of each group will be calculated mean ± standard deviation, and
compared by statistical analysis.
Patients with acute ischemic stroke will be divided into 2 groups by double-blind,
randomized, and controlled trial. Personality and past history of the patients will be
recorded after the patients signed inform consent. The patient will be collected blood among
10 cc. for measurement biomarker in serum that related plaque stability i.e. sLOX-1 and NO
levels for baseline and obtained neurological examination i.e. NIHSS, mRS and Barthel's index
scale for baseline. The bloods will be centrifuged 4,000 rpm for 15 minutes at 4˚C. The
supernatant will be collected for determine sLOX-1 and NO levels by ELIZA.
The patients must be take pills for 180 days by randomized code number on pill box, and
patients must be turn into the site for follow up visit at Day 90 and Day 180. All visits of
the patients will be collected blood among 10 cc. for measurement biomarker in serum that
related plaque stability i.e. sLOX-1 and NO, and obtained neurological examination i.e.
NIHSS, mRS and Barthel's index scale. The bloods were centrifuged 4,000 rpm for 15 minutes at
4˚C. The supernatant were collected for determine all biomarkers by ELIZA.
Next, the data will be separated with code number for divided group into 2 groups. Group 1 is
simvastatin 10 mg per day treatment (n=36) and Group 2 is simvastatin 40 mg per day treatment
(n=36) . Finally, all data of each group will be calculated mean ± standard deviation, and
compared by statistical analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Not yet recruiting |
NCT01923818 -
Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
|
Phase 2/Phase 3 |